MX9806292A - Formulacion de un inhibidor de la 5alfa-reductasa para su administracion oral, y un procedimiento de preparacion y uso del mismo. - Google Patents

Formulacion de un inhibidor de la 5alfa-reductasa para su administracion oral, y un procedimiento de preparacion y uso del mismo.

Info

Publication number
MX9806292A
MX9806292A MX9806292A MX9806292A MX9806292A MX 9806292 A MX9806292 A MX 9806292A MX 9806292 A MX9806292 A MX 9806292A MX 9806292 A MX9806292 A MX 9806292A MX 9806292 A MX9806292 A MX 9806292A
Authority
MX
Mexico
Prior art keywords
alpha
oral administration
producing
same
reductase inhibitory
Prior art date
Application number
MX9806292A
Other languages
English (en)
Inventor
Fusao Usui
Yuko Ohuchi
Akira Kusai
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of MX9806292A publication Critical patent/MX9806292A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una formulacion de un inhibidor de la 5&-reductasa para su administracion oral, la cual comprende una composicion que se obtiene triturando una mezcla de un azasteroide, un polímero soluble en agua y un desintegrante.
MX9806292A 1996-02-05 1998-08-04 Formulacion de un inhibidor de la 5alfa-reductasa para su administracion oral, y un procedimiento de preparacion y uso del mismo. MX9806292A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP1871896 1996-02-05

Publications (1)

Publication Number Publication Date
MX9806292A true MX9806292A (es) 1998-11-30

Family

ID=11979447

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9806292A MX9806292A (es) 1996-02-05 1998-08-04 Formulacion de un inhibidor de la 5alfa-reductasa para su administracion oral, y un procedimiento de preparacion y uso del mismo.

Country Status (18)

Country Link
US (1) US20020015732A1 (es)
EP (1) EP0923942B1 (es)
KR (1) KR19990082277A (es)
CN (1) CN1215339A (es)
AT (1) ATE208631T1 (es)
AU (1) AU709146B2 (es)
CZ (1) CZ289856B6 (es)
DE (1) DE69708307T2 (es)
DK (1) DK0923942T3 (es)
ES (1) ES2165017T3 (es)
HK (1) HK1020258A1 (es)
HU (1) HUP9901870A3 (es)
MX (1) MX9806292A (es)
NO (1) NO983580L (es)
NZ (1) NZ326897A (es)
PT (1) PT923942E (es)
RU (1) RU2154467C2 (es)
WO (1) WO1997027875A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ337048A (en) * 1997-02-26 2000-10-27 Sankyo Co Use of N-[1-methyl-(substituted phenyl)ethyl]-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide derivatives to treat prostate cancer
ATE262337T1 (de) * 1997-07-29 2004-04-15 Sankyo Co Azasteroidverbindung zur behandlung von alopezie, hirsutismus und seborrhoe
CN110628735B (zh) * 2019-04-23 2022-04-08 天津科技大学 一种5α-还原酶突变体，基因工程菌及其在高效催化5α-AD生产中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8403359D0 (en) * 1984-02-08 1984-03-14 Erba Farmitalia Pharmaceutical compositions
ZA851426B (en) * 1984-02-27 1986-10-29 Merck & Co Inc 17 beta-n-monosubstituted carbamoyl-4-aza-5 alpha-androst-1-en-3-ones as 5 alpha reductase inhibitors
IE76452B1 (en) * 1990-10-29 1997-10-22 Sankyo Co Azasteroid compounds for the treatment of prostatic hypertrophy their preparation and use
JPH06293793A (ja) * 1993-02-10 1994-10-21 Sankyo Co Ltd ステロイド−１７−アミド類の製造法

Also Published As

Publication number Publication date
EP0923942A1 (en) 1999-06-23
CZ234298A3 (cs) 1998-11-11
WO1997027875A1 (fr) 1997-08-07
US20020015732A1 (en) 2002-02-07
AU709146B2 (en) 1999-08-19
HK1020258A1 (en) 2000-04-07
CZ289856B6 (cs) 2002-04-17
DK0923942T3 (da) 2001-12-17
HUP9901870A3 (en) 1999-11-29
DE69708307T2 (de) 2002-08-14
ES2165017T3 (es) 2002-03-01
NO983580D0 (no) 1998-08-04
NZ326897A (en) 1999-08-30
EP0923942A4 (es) 1999-06-23
PT923942E (pt) 2002-03-28
HUP9901870A2 (hu) 1999-09-28
KR19990082277A (ko) 1999-11-25
CN1215339A (zh) 1999-04-28
RU2154467C2 (ru) 2000-08-20
DE69708307D1 (de) 2001-12-20
EP0923942B1 (en) 2001-11-14
NO983580L (no) 1998-10-02
AU1558997A (en) 1997-08-22
ATE208631T1 (de) 2001-11-15

Similar Documents

Publication Publication Date Title
AU1729397A (en) Process to prepare soluble delivery systems using volatile salts
AU7123296A (en) Liposomal formulations of mitoxantrone
AU6564794A (en) Use of nona- and decapeptides in the preparation of a drug for the treatment of aids
AU4867697A (en) Oxadiazoles, processes for preparing them and their use as pharmaceutical compositions
CA2186260A1 (en) Composition comprising morphine, polypyrrolidone and a polyalkyleneoxide
BG105564A (en) Galantamine-containing composition with controlled release
MY119403A (en) Novel compounds with analgesic effect.
MXPA94003094A (es) Polimero en barra rigido, a base de piridobisimidazol.
CA2273354A1 (en) Oxyiminopregnanecarbolactones
MX9601069A (es) Nuevas pirido /3,2-e/pirazinonas con efecto antiasmatico y procedimiento para su preparacion.
AU4871797A (en) Magnesium (-)hydroxycitrate, preparation process, uses and compositions, in particular pharmaceutical compositions, containing it
HUP0000426A3 (en) Novel benzonaphthyridines, pharmaceutical compositions and use thereof and process for their preparation
CA2182207A1 (en) Paramunity Inducer Based on Combinations of Poxvirus Components, Process to Prepare It and Its Use as Medicament
CA2262566A1 (en) Benzamidine derivatives and the use thereof as medicaments with ltb4-antagonistic effect
IL132599A0 (en) Substituted 3,3-diamino-2-propenenitriles their preparation and use
AU4134297A (en) 2,4-disubstituted pyrimidine derivatives, process for producing the same, and medicinal compositions containing the same
ZA9610460B (en) New phenylamidine derivatives, processes for preparing them and their use as pharmaceutical compositions.
BG101401A (en) Cisaspide extended release oral compositions
HUP9602868A3 (en) 1,7,7-trimethyl-bicyclo[2.2.1]heptane derivative, pharmaceutical compositions containing the same and process for their preparation
MY120550A (en) Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-10-ols, processes for preparing them and their use as pharmaceutical compositions.
AU3808795A (en) Water-soluble derivatives of epipodophyllotoxin, process for their preparation, their use as medicinal product and their intended use in anticancer treatments
MX9806292A (es) Formulacion de un inhibidor de la 5alfa-reductasa para su administracion oral, y un procedimiento de preparacion y uso del mismo.
BG105204A (en) Salts of paroxetine
EP0717618A4 (en) STABILIZED FORMULATION FOR TABLETS
AU4845196A (en) 2-sulfinylnicotinamide derivatives, intermediate thereof, process for producing 2-sulfinylnicotinamide derivatives, and medicinal composition containing the same as active ingredient